Management of Chemotherapy-Ineligible AML: Beyond HMA Monotherapy - Episode 6

Practical Considerations for Venetoclax Plus HMA for Chemotherapy-Ineligible AML

August 3, 2021

Dr Stein elaborates on some practical considerations for the use of venetoclax and hypomethylating agents for the treatment of patients with chemotherapy-ineligible acute myeloid leukemia.

EP. 1: Standard of Care for Newly Diagnosed Adult Patients With AML

EP. 2: Approval of Small Molecular Inhibitors for Patients With AML

EP. 3: First-Line Treatments for Chemotherapy-Ineligible AML

EP. 4: Predictive and Prognostic Factors In Chemotherapy-Ineligible AML

EP. 5: First-Line Treatment Considerations for Chemotherapy-Ineligible AML

Now Viewing

EP. 6: Practical Considerations for Venetoclax Plus HMA for Chemotherapy-Ineligible AML

EP. 7: Promising First-Line Therapeutic Approaches for Adult Patients With AML

EP. 8: Management of Chemotherapy-Ineligible Acute Myeloid Leukemia: Beyond Hypomethylating Agent Monotherapy